Three years ago, Tarsus Pharmaceuticals was shrinking. Revenue had fallen by more than half in 2022, then fell again in 2023, and the company was burning through cash on a drug that hadn’t yet found its commercial footing. Then XDEMVY, a prescription eye drop that kills the mite responsible for a common eyelid condition called Demodex blepharitis, launched in earnest. Full-year 2025 revenue hit $451 million, nearly ten times what the company booked in 2023. Now Tarsus is spending that momentum on two acquisitions closed within sixty days of each other, and the filing tells two stories at once: a business finally generating real sales, and a pipeline that just got significantly more complicated.
The story, briefly
The math shows a company that went from near-zero commercial revenue to nearly half a billion dollars in annual sales in two years, driven almost entirely by one product. The mood, measured by today’s price of $68.07, sits well below the 52-week high, and our data shows the stock trading at a price-to-sales ratio of 6.9 against its own historical median of 16.4, meaning the market is paying far less per dollar of sales than it has historically. The open question is whether two rapid acquisitions deepen the story or dilute it, and the filing cannot yet answer that.
What the filing actually says
The 10-Q for the quarter ended June 30, 2026 shows XDEMVY net product sales of $173.9 million for the second quarter alone, up sharply from the same quarter a year earlier. To feel the scale: that single quarter’s sales exceed what the entire company booked across all of 2023. The net loss narrowed in Q2 2026 compared to Q2 2025, meaning Tarsus is losing less money even as it spends more. Cash on hand at June 30 stood at $449.7 million, roughly equal to a full year of 2025 revenue, which matters because both acquisitions closed after that date.
The company raised its full-year 2026 sales guidance for XDEMVY to a range centered near $695 million. If the second half of 2026 delivers on that range, annual revenue would be growing at a pace that makes the 2025 figure look like a warmup lap.
Two deals, sixty days apart
On July 6, 2026, Tarsus completed the acquisition of iRenix Medical, adding IRX-101, an investigational antiseptic for the eye, to its pipeline. Then on September 4, 2026, it closed the acquisition of Alkeus Pharmaceuticals, bringing in a Phase 3 program for Stargardt disease, a rare inherited condition that destroys central vision, typically in children and young adults. Neither deal’s financial terms appear in the dossier, so we cannot say what Tarsus paid or how much of its cash cushion remains. That is a genuine gap in what the public record currently shows.
What the sequence does show is a deliberate pivot. Tarsus built its commercial identity on the eyelid surface. Stargardt disease sits in the retina, a different tissue, a different patient population, and a different regulatory pathway. Adding a Phase 3 retina program while simultaneously running Phase 2 trials for ocular rosacea (TP-04) and Lyme disease prevention (TP-05) means the company is now managing four distinct clinical bets alongside one commercial product. That is a lot of plates for an organization that, as recently as 2023, had barely found its commercial footing.
What compounds, and what doesn’t yet
The word “compounds” here carries its pharmaceutical meaning, but it also describes what happens financially when a single revenue source funds an expanding pipeline. Each dollar XDEMVY earns is doing double duty: it covers operating losses and it underwrites the next set of clinical trials. The narrowing net loss in Q2 2026 suggests that math is moving in the right direction. But the Alkeus acquisition, closed after the June 30 balance sheet date, means the cash figure in the filing is already stale in ways the filing itself acknowledges it cannot fully quantify.
The pipeline that existed before the acquisitions, TP-04 and TP-05, was already a stretch from XDEMVY’s commercial lane. TP-05 for Lyme disease prevention is particularly far afield from ophthalmology. Now add a retina program. The dossier contains no management commentary specific to Tarsus on how these programs are being prioritized relative to one another, so we cannot report on internal resource allocation with any precision.
Reading the numbers
- $173.9 million, Q2 2026 XDEMVY sales. This is what one product sold in one quarter. It means Tarsus has genuine commercial scale now, not just a launch story. A company earning at this rate in a single quarter has real negotiating leverage with partners and real capacity to fund trials internally. Source: 10-Q, June 30, 2026.
- $449.7 million in cash at June 30, 2026. Think of this as roughly a year’s worth of 2025 revenue sitting in the bank. It is the buffer that makes two acquisitions in sixty days possible. The catch: both deals closed after this date, so the actual remaining balance is unknown from public filings as of today. Source: 10-Q, June 30, 2026.
- P/S ratio of 6.9 versus a historical median of 16.4. A price-to-sales ratio is the price tag the market puts on each dollar of annual revenue. At 6.9, the market is paying less than half its own historical rate for each dollar Tarsus earns. Our data places this at the 9th percentile of the company’s own history, meaning the stock has rarely been cheaper relative to sales. Whether that reflects a genuine discount or a genuine concern about pipeline complexity is the question the filing raises but cannot resolve. Source: our data, computed from SEC filings and market prices.
- $685 million to $705 million, full-year 2026 XDEMVY guidance. If the second half delivers, annual revenue roughly doubles from 2025. That would be the third consecutive year of dramatic growth from a single approved drug. Source: TradingView, citing the 10-Q summary.
The business that filed this quarter looks nothing like the one that filed three years ago. Whether the pipeline it just bought earns the same transformation is a question the next several filings will have to answer.
Sources
- 10-Q for quarter ended June 30, 2026
- 10-K for fiscal year ended December 31, 2025
- 10-K for fiscal year ended December 31, 2024
- 10-K for fiscal year ended December 31, 2023
- TradingView: Tarsus Q2 2026 10-Q summary
- StockTitan: Tarsus SEC filings
